➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 8,158,360

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,158,360
Title:Effects of inhibitors of FGFR3 on gene transcription
Abstract: Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to FGFR3 inhibition, are measured and identifications or adjustments may be made accordingly.
Inventor(s): Heise; Carla (Benicia, CA), Masih-Khan; Esther (Ontario, CA), Moler; Edward (Walnut Creek, CA), Rowe; Michael (Oakland, CA), Stewart; Keith (Scottsdale, AZ), Trudel; Suzanne (Ontario, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:12/096,222
Patent Claims:see list of patent claims

Details for Patent 8,158,360

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Novartis AG (Basel, CH) 2025-12-08 RX search
Akorn Inc HYDASE hyaluronidase INJECTABLE;INJECTION 021716 001 2005-10-25   Start Trial Novartis AG (Basel, CH) 2025-12-08 DISCN search
Amphastar Pharm AMPHADASE hyaluronidase INJECTABLE;INJECTION 021665 001 2005-11-03   Start Trial Novartis AG (Basel, CH) 2025-12-08 RX search
Bausch And Lomb VITRASE hyaluronidase INJECTABLE;INJECTION 021640 002 2004-12-21   Start Trial Novartis AG (Basel, CH) 2025-12-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.